Skip to main content
Premium Trial:

Request an Annual Quote

Caprotec Touts Success of CCMS Technology in Drug Development Study with Roche

Premium

Caprotec Bioanalytics said this week that it has successfully completed a collaboration with Roche that used the company's Capture Compound Mass Spectroscopy platform to analyze the interaction of an undisclosed drug candidate with human protein targets.

Caprotec said it was able to demonstrate that among the protein targets binding specifically to the drug in question were proteins showing activity in pathways commensurate with the drug candidate's phenotypic profile.

CCMS technology is based on capture compounds that isolate functionally selected proteins on the basis of small molecule-protein interactions. The company currently sells kits for the study of seven protein classes – its cAMP, cGMP, GDP, Stauro, SAH, SAHA, and Marimastat caproKits.

In the January 2010 issue of Toxicological Sciences, a team of researchers including Caprotec CEO Hubert Koster published a study in which they used CCMS to investigate the molecular basis for side effects caused by two Parkinson's disease drugs: tolcapone, developed by Roche; and entacapone, marketed by Novartis under the trade name Comtan.

In May, the company completed a $5.1 million funding round. At the time, Ute Mercker, senior investment manager at Caprotec investor IBB Beteiligungsgesellschaft, told ProteoMonitor that the round marked a shift towards increased emphasis on the company's ImproMed division, which applies the CCMS technology in drug development efforts such as the recent collaboration with Roche (PM 05/21/2010).

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.